CYCN
Cyclerion Therapeutics, Inc.
Set alert
3.36 USD -20.16 -85.71%
23.52 Day range 23.52
1.27 52-week range 9.47
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 3.72
- Prev close
- 23.52
- Mkt cap
- 8.67M
- Vol
- 435.85K
- Avg vol
- 3.11M
- EPS
- -2.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 23.52
- High
- 23.52
- Forward P/E
- -2.44
- Beta
- 1.92
- Short ratio
- 0.78
- Inst. own
- 40.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 27, 2024
- 50-d avg
- 2.76
- 200-d avg
- 2.87
- 1y target
- 0.00
Key statistics
- Market cap
- 8.67M
- Enterprise value
- 1.90M
- Trailing P/E
- 0.00
- Forward P/E
- -2.44
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.70
- EPS (TTM)
- -2.08
- Beta
- 1.92
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -6.39M
- Total cash
- 4.59M
- Total debt
- 0
- Return on equity
- -150.25%
- Shares outstanding
- 2.71M
- Short % of float
- 0.87%
- 50-day average
- 2.76
- 200-day average
- 2.87
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Mar 27, 2024
Expected Mar 27, 2024. Consensus EPS estimate 0.00.
Financials — quick view
CYCN Revenue — quarterly 0
CYCN Net income — quarterly -1.75M
CYCN EPS — quarterly -2.87
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.29 | — | — |
| Aug 7, 2024 | Jun 1, 2024 | 0.00 | -0.53 | — | — |
| May 7, 2024 | Mar 1, 2024 | 0.00 | -0.62 | — | — |
| Mar 27, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.93 | — | — |
| Jul 28, 2023 | Jun 1, 2023 | 0.00 | -1.83 | — | — |
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cyclerion.com
News
- Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
- 12 Health Care Stocks Moving In Friday's Intraday Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy
- SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)
Your note
Sign in to keep a note on CYCN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DESOUZA ERROL B | Director | Stock Award(Grant) | Nov 29, 2023 | 30,000 |
| GRAUL REGINA MARGARET | President | Stock Award(Grant) | Dec 28, 2023 | 100,303 |
| HECHT PETER M | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Dec 28, 2023 | 377,457 |
| HYMAN STEVEN | Director | Stock Award(Grant) | Nov 29, 2023 | 20,000 |
| MCGUIRE TERRANCE G | Director | Stock Award(Grant) | Nov 29, 2023 | 42,010 |
| SLATE PATH CAPITAL LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 20, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Slate Path Capital, LP | 13.21% | 357,880 | 1.15M | Sep 29, 2024 |
| MFN Partners Management, LP | 6.25% | 169,460 | 542.27K | Sep 29, 2024 |
| Tyndall Capital Partners LP | 6.08% | 164,777 | 527.29K | Sep 29, 2024 |
| FMR, LLC | 5.82% | 157,636 | 504.44K | Sep 29, 2024 |
| Siren, L.L.C. | 4.29% | 116,155 | 371.70K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.25% | 33,908 | 108.50K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.87% | 23,490 | 75.17K | Sep 29, 2024 |
| Fidelity Growth Company Fund | 0.76% | 20,564 | 65.80K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index ETF | 0.52% | 14,078 | 45.05K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.40% | 10,826 | 34.64K | Oct 30, 2024 |
| Fidelity Growth Company K6 Fund | 0.34% | 9,220 | 29.50K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 2,325 | 7.44K | Oct 30, 2024 |